Free Trial

Contineum Therapeutics (CTNM) Stock Price, News & Analysis

+0.25 (+1.58%)
(As of 05/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
118,222 shs
Average Volume
76,057 shs
Market Capitalization
$294.10 million
P/E Ratio
Dividend Yield
Price Target

About Contineum Therapeutics

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

CTNM Stock Price History

CTNM Stock News Headlines

See More Headlines
Receive CTNM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Contineum Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Pretax Margin


Sales & Book Value

Annual Sales
$50 million


Free Float
Market Cap
$294.10 million
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Carmine N. Stengone MBA (Age 48)
    MS, President, CEO, Secretary & Director
    Comp: $790.3k
  • Mr. Peter T. Slover CPA (Age 49)
    Chief Financial Officer
    Comp: $569.7k
  • Dr. Daniel S. Lorrain Ph.D. (Age 55)
    Chief Science Officer
    Comp: $565.02k
  • Dr. Stephen L. Huhn F.A.A.P (Age 63)
    F.A.C.S., M.D., Chief Medical Officer & Senior VP of Clinical Development
  • Mr. Austin Chen Ph.D.
    SVP & Head of Research
  • Mr. Michael Mayberry
    Senior Director & Corporate Controller

CTNM Stock Analysis - Frequently Asked Questions

Should I buy or sell Contineum Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Contineum Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CTNM shares.
View CTNM analyst ratings
or view top-rated stocks.

What is Contineum Therapeutics' stock price target for 2024?

3 analysts have issued 1-year price objectives for Contineum Therapeutics' stock. Their CTNM share price targets range from $25.00 to $30.00. On average, they expect the company's stock price to reach $28.00 in the next year. This suggests a possible upside of 73.8% from the stock's current price.
View analysts price targets for CTNM
or view top-rated stocks among Wall Street analysts.

How have CTNM shares performed in 2024?

Contineum Therapeutics' stock was trading at $15.40 at the start of the year. Since then, CTNM stock has increased by 4.6% and is now trading at $16.11.
View the best growth stocks for 2024 here

When is Contineum Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 15th 2024.
View our CTNM earnings forecast

When did Contineum Therapeutics IPO?

Contineum Therapeutics (CTNM) raised $110 million in an initial public offering on Friday, April 5th 2024. The company issued 6,875,000 shares at a price of $16.00 per share.

When did the company's quiet period expire?

Contineum Therapeutics' quiet period expired on Wednesday, May 15th. Contineum Therapeutics had issued 6,875,000 shares in its public offering on April 5th. The total size of the offering was $110,000,000 based on an initial share price of $16.00. During the company's quiet period, insiders and underwriters involved in the IPO were prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Contineum Therapeutics?

Shares of CTNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CTNM) was last updated on 5/24/2024 by Staff

From Our Partners